You are here: Industry Insights > Novartis

News List

Novartis appoints Rob Kowalski as Chief People & Organization Officer americanpharmaceuticalreview
June 30, 2021
Novartis announced the appointment of Rob Kowalski, Pharm.D., Global Head Regulatory Affairs and US Head of Drug Development as Chief People & Organization Officer.
Global API market to value $300 billion by 2030 europeanpharmaceuticalreview
June 25, 2021
Researchers anticipate the growth of the aging population and rising investment in biologic drugs to promote the expansion of the global active pharmaceutical ingredient (API) market.
Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts worldpharmanews
June 24, 2021
Novartis and Hewlett Packard Enterprise (HPE)announced a collaboration that aims to accelerate the use of data and digital technologies within Novartis efforts to reimagine global health and improve access to healthcare and medicines.
Novartis reveals long-term results for MS therapy Kesimpta pharmatimes
June 24, 2021
Novartis has revealed new long-term data for its B-cell targeting therapy Kesimpta, showing that mean immunoglobulin G (IgG) and immunoglobulin M (IgM) were preserved in adults with relapsing multiple sclerosis (MS) receiving the therapy over 3.5 years.
Novartis aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021 firstwordpharma
June 23, 2021
Novartis aims to bottle more than 50 million doses of BioNTech’s COVID-19 vaccine this year at its fill-and-finish facility in Stein, Switzerland, as reported in KFGO.
Zolgensma shows promise in presymptomatic SMA patients pharmatimes
June 22, 2021
Novartis’ gene therapy Zolgensma has shown benefit for presymptomatic spinal muscular atrophy (SMA) patients, according to new data presented at the annual European Academy for Neurology (EAN) virtual congress.
Novartis’ radioligand therapy granted US Breakthrough Therapy Designation pharmatimes
June 22, 2021
Swiss pharma company Novartis has scored a Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration for its investigational radioligand therapy Lu-PSMA-617.
Novartis’ Cosentyx wins NICE backing for non-radiographic axial spondyloarthritis pharmatimes
June 21, 2021
Novartis’ Cosentyx has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA).
Novartis prostate cancer drug gets FDA breakthrough designation pharmaceutical-technology
June 18, 2021
The FDA breakthrough designation is based on positive results from the Phase III VISION study of ¹⁷⁷Lu-PSMA-617.
Novartis cedes US operations for migraine drug Aimovig to Amgen firstwordpharma
June 17, 2021
Novartis will transfer previously shared US business operations for the anti-CGRP migraine therapy Aimovig (erenumab) to its partner Amgen, the companies confirmed to FirstWord Pharma on Wednesday.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page